Sign In
Buy PLSE
$24.99
+0.710 (+2.92%)
At Close: Jun 03, 2026
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
04:05pm, Wednesday, 27'th May 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
01:00pm, Tuesday, 26'th May 2026
Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
10:42am, Sunday, 17'th May 2026
Pulse Biosciences, a developer of non-thermal bioelectric treatments, reported a notable insider buy amid recent stock price gains.
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
09:30pm, Wednesday, 13'th May 2026
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
07:00am, Tuesday, 12'th May 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co
Pulse Biosciences Q1 Earnings Call Highlights
04:16pm, Friday, 08'th May 2026
Pulse Biosciences NASDAQ: PLSE said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
07:00am, Friday, 08'th May 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
12:01am, Friday, 08'th May 2026
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Thursday, 07'th May 2026
Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
09:06am, Monday, 04'th May 2026
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
07:00am, Monday, 04'th May 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ene
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript
08:41pm, Saturday, 25'th Apr 2026
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
01:00pm, Saturday, 25'th Apr 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ene
Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
07:00am, Monday, 20'th Apr 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced tha
Pulse Biosciences to Host Analyst Event on April 25, 2026
07:00am, Friday, 17'th Apr 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans
